An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Afzal MZ 

PROVIDER: S-EPMC6462590 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature